PDF(Pubmed)
Abstract：
UNASSIGNED: Thyroid hormones play an important role in the regulation of diverse metabolic processes and might play a crucial role in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). However, their association remains controversial. Therefore, our aim is to clarify whether overt or subclinical hypothyroidism was associated with NAFLD.
UNASSIGNED: This cross-sectional study included 60 participants with a new diagnosis of hypothyroidism and 30 age- and gender-matched healthy participants with thyroid-stimulating hormone (TSH) level <4.5 mIU/L. Anthropometric measurements, laboratory parameters, plasma fibroblast growth factor 21 (FGF21), and hepatic steatosis diagnosed via controlled attenuation parameter (CAP) using transient elastography between the hypothyroid groups and control group were analyzed.
UNASSIGNED: Participants with hypothyroidism displayed significantly higher serum aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, total cholestrol, triglycerides, low-density lipoprotein cholesterol, TSH, hemoglobin A1c, fasting insulin, and homeostatic model assessment of insulin resistance (HOMA-IR) but significantly lower serum albumin, high-density lipoprotein cholesterol, and free thyroxine levels than the control group (P = <0.001). The CAP values were significantly higher in participants with overt and subclinical hypothyroidism than the control group (P = <0.001). The only significant independent predictors of steatosis in our study were free T4, body mass index, and HOMA-IR after using multivariate logistic regression. The mean serum FGF21 levels were increased in hypothyroid participants with hepatic steatosis than those without hepatic steatosis (126.9 ± 272.6) pg/ml vs. (106.8 ± 138.7) pg/ml, P = 0.8). Receiver operating characteristic (ROC) curve showed that FGF21 was not a significant marker for hepatic steatosis in hypothyroid participants (area under curve (AUC) = 0.44, P = 0.54).
UNASSIGNED: Individuals with subclinical or overt hypothyroidism were more likely to have NAFLD than those with normal thyroid function. Serum FGF21 levels were increased in hypothyroid individuals and its role as a marker of hepatic steatosis in hypothyroid individuals needs further assessment.
UNASSIGNED: This cross-sectional study included 60 participants with a new diagnosis of hypothyroidism and 30 age- and gender-matched healthy participants with thyroid-stimulating hormone (TSH) level <4.5 mIU/L. Anthropometric measurements, laboratory parameters, plasma fibroblast growth factor 21 (FGF21), and hepatic steatosis diagnosed via controlled attenuation parameter (CAP) using transient elastography between the hypothyroid groups and control group were analyzed.
UNASSIGNED: Participants with hypothyroidism displayed significantly higher serum aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, total cholestrol, triglycerides, low-density lipoprotein cholesterol, TSH, hemoglobin A1c, fasting insulin, and homeostatic model assessment of insulin resistance (HOMA-IR) but significantly lower serum albumin, high-density lipoprotein cholesterol, and free thyroxine levels than the control group (P = <0.001). The CAP values were significantly higher in participants with overt and subclinical hypothyroidism than the control group (P = <0.001). The only significant independent predictors of steatosis in our study were free T4, body mass index, and HOMA-IR after using multivariate logistic regression. The mean serum FGF21 levels were increased in hypothyroid participants with hepatic steatosis than those without hepatic steatosis (126.9 ± 272.6) pg/ml vs. (106.8 ± 138.7) pg/ml, P = 0.8). Receiver operating characteristic (ROC) curve showed that FGF21 was not a significant marker for hepatic steatosis in hypothyroid participants (area under curve (AUC) = 0.44, P = 0.54).
UNASSIGNED: Individuals with subclinical or overt hypothyroidism were more likely to have NAFLD than those with normal thyroid function. Serum FGF21 levels were increased in hypothyroid individuals and its role as a marker of hepatic steatosis in hypothyroid individuals needs further assessment.
摘要：
■甲状腺激素在调节多种代谢过程中起重要作用，并且可能在非酒精性脂肪性肝病（NAFLD）的发病机理中起关键作用。然而,他们的关系仍然存在争议。因此,我们的目的是明确明显或亚临床甲状腺功能减退症是否与NAFLD相关.
这项横断面研究包括60名新诊断为甲状腺功能减退的参与者和30名年龄和性别匹配的健康参与者，甲状腺刺激激素（TSH）水平<4.5mIU/L人体测量,实验室参数,血浆成纤维细胞生长因子21（FGF21），分析甲状腺功能减退组和对照组通过瞬时弹性成像控制衰减参数（CAP）诊断的肝脂肪变性。
■甲状腺功能减退症患者的血清天冬氨酸转氨酶明显升高，丙氨酸氨基转移酶，γ-谷氨酰转移酶,总胆固醇,甘油三酯，低密度脂蛋白胆固醇，TSH,血红蛋白A1c，空腹胰岛素，和胰岛素抵抗（HOMA-IR）的稳态模型评估，但显著降低血清白蛋白，高密度脂蛋白胆固醇，而游离甲状腺素水平高于对照组(P=<0.001)。明显和亚临床甲状腺功能减退症患者的CAP值明显高于对照组（P=<0.001）。在我们的研究中，脂肪变性的唯一显著的独立预测因子是游离T4，体重指数，和HOMA-IR后使用多变量逻辑回归。有肝性脂肪变性的甲状腺功能减退参与者的平均血清FGF21水平比没有肝性脂肪变性的参与者增加（126.9±272.6）pg/ml与(106.8±138.7)pg/ml,P=0.8)。受试者工作特征（ROC）曲线显示，FGF21不是甲状腺功能减退参与者肝脏脂肪变性的显著标志物（曲线下面积（AUC）=0.44，P=0.54）。
■患有亚临床或明显甲状腺功能减退症的人比甲状腺功能正常的人更容易患NAFLD。甲状腺功能减退个体的血清FGF21水平升高，其作为甲状腺功能减退个体的肝脂肪变性标志物的作用需要进一步评估。
这项横断面研究包括60名新诊断为甲状腺功能减退的参与者和30名年龄和性别匹配的健康参与者，甲状腺刺激激素（TSH）水平<4.5mIU/L人体测量,实验室参数,血浆成纤维细胞生长因子21（FGF21），分析甲状腺功能减退组和对照组通过瞬时弹性成像控制衰减参数（CAP）诊断的肝脂肪变性。
■甲状腺功能减退症患者的血清天冬氨酸转氨酶明显升高，丙氨酸氨基转移酶，γ-谷氨酰转移酶,总胆固醇,甘油三酯，低密度脂蛋白胆固醇，TSH,血红蛋白A1c，空腹胰岛素，和胰岛素抵抗（HOMA-IR）的稳态模型评估，但显著降低血清白蛋白，高密度脂蛋白胆固醇，而游离甲状腺素水平高于对照组(P=<0.001)。明显和亚临床甲状腺功能减退症患者的CAP值明显高于对照组（P=<0.001）。在我们的研究中，脂肪变性的唯一显著的独立预测因子是游离T4，体重指数，和HOMA-IR后使用多变量逻辑回归。有肝性脂肪变性的甲状腺功能减退参与者的平均血清FGF21水平比没有肝性脂肪变性的参与者增加（126.9±272.6）pg/ml与(106.8±138.7)pg/ml,P=0.8)。受试者工作特征（ROC）曲线显示，FGF21不是甲状腺功能减退参与者肝脏脂肪变性的显著标志物（曲线下面积（AUC）=0.44，P=0.54）。
■患有亚临床或明显甲状腺功能减退症的人比甲状腺功能正常的人更容易患NAFLD。甲状腺功能减退个体的血清FGF21水平升高，其作为甲状腺功能减退个体的肝脂肪变性标志物的作用需要进一步评估。
